SCHEMBL3018743

SCHEMBL3018743

CCOC(=O)C(=O)c1cccc(Cl)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.51
GAA P10253 1/20 0.51
ELANE P08246 1/20 0.49
ALDH1A1 P00352 3/20 0.49
PARP1 P09874 1/20 0.49
TRPV1 Q8NER1 1/20 0.48
XPO1 O14980 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
LMNA P02545 2/20 0.46
GPR35 Q9HC97 1/20 0.46
KMT2A Q03164 1/20 0.46
CHRM2 P08172 1/20 0.46
CHRM4 P08173 1/20 0.46
CHRM1 P11229 1/20 0.46
CHRM3 P20309 1/20 0.46
HPGD P15428 2/20 0.46
TP53 P04637 1/20 0.45
KYAT1 Q16773 1/20 0.45
ERCC5 P28715 1/20 0.45
FEN1 P39748 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27611205 0.90 MAPT (0.58) MAPTGAAELANEALDH1A1TRPV1
SCHEMBL9863135 0.88 ALDH1A1 (0.56) MAPTALDH1A1SMN1; SMN2GPR35KMT2A
SCHEMBL3903964 0.84 XPO1 (0.51) MAPTGAAELANEALDH1A1PARP1
SCHEMBL197307 0.83 TRPV1 (0.61) ELANEALDH1A1PARP1TRPV1SMN1; SMN2
SCHEMBL29443099 0.83 TRPV1 (0.61) ELANEALDH1A1PARP1TRPV1SMN1; SMN2
SCHEMBL2007367 0.83 TDP1 (0.53) MAPTGAAELANEALDH1A1PARP1
SCHEMBL1704844 0.82 ABCB1 (0.47) MAPTGAAALDH1A1SMN1; SMN2GPR35
SCHEMBL11365918 0.82 MAPT (0.51) MAPTGAAELANEALDH1A1TRPV1
SCHEMBL11365920 0.82 MAPT (0.51) MAPTGAAELANEALDH1A1TRPV1
SCHEMBL11631222 0.81 PARP1 (0.51) MAPTGAAELANEALDH1A1PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12624010-B2 Dihydrooxazole and thiourea derivatives modulating the NLRP3 inflammasome pathway AC IMMUNE SA (CH) 2026-05-12 US disclosed
EP-4168395-B1 DIHYDROOXAZOLE AND THIOUREA OR UREA DERIVATIVES MODULATING THE NLRP3 INFLAMMASOME PATHWAY AC IMMUNE SA (CH) 2026-03-25 EP disclosed
US-20230250070-A1 DIHYDROOXAZOLE AND THIOUREA DERIVATIVES MODULATING THE NLRP3 INFLAMMASOME PATHWAY AC IMMUNE SA (CH) 2023-08-10 US disclosed
US-20230250070-A1 DIHYDROOXAZOLE AND THIOUREA DERIVATIVES MODULATING THE NLRP3 INFLAMMASOME PATHWAY AC IMMUNE SA (CH) 2023-08-10 US disclosed
EP-4168395-A1 DIHYDROOXAZOLE AND THIOUREA OR UREA DERIVATIVES MODULATING THE NLRP3 INFLAMMASOME PATHWAY AC Immune SA (CH) 2023-04-26 EP disclosed
CN-115768754-A Dihydrooxazole and thiourea or urea derivatives that modulate NLRP3 inflammasome pathways AC免疫有限公司 2023-03-07 CN disclosed
WO-2021255279-A1 D I H YD ROOXAZO LE AND THIOUREA DERIVATIVES MODULATING THE NLRP3 INFLAMMASOME PATHWAY AC IMMUNE SA (CH) 2021-12-23 WO disclosed
WO-2021255279-A1 D I H YD ROOXAZO LE AND THIOUREA DERIVATIVES MODULATING THE NLRP3 INFLAMMASOME PATHWAY AC IMMUNE SA (CH) 2021-12-23 WO disclosed
CN-108699106-B Novel trifluoromethylpropionamide derivatives as HTRA1 inhibitors 豪夫迈·罗氏有限公司 2021-11-30 CN disclosed
US-11014963-B2 Trifluoromethylpropanamide derivatives as HTRA1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2021-05-25 US disclosed
US-7723336-B2 Fused heterocyclic compounds useful as kinase modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2010-05-25 US disclosed
US-20080045536-A1 FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2008-02-21 US disclosed
US-20070043000-A1 Immunosuppresive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2007-02-22 US disclosed
US-7144899-B2 Thrombin inhibitors MERCK & CO., INC. (US) 2006-12-05 US disclosed
EP-1636232-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA Bioscience nv (BE) 2006-03-22 EP disclosed
WO-2004104005-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA BIOSCIENCE NV (BE) 2004-12-02 WO disclosed
EP-1479682-A1 Immunosuppressive effects of pteridine derivatives 4 AZA Bioscience nv (BE) 2004-11-24 EP disclosed
US-20040073025-A1 Thrombin inhibitors MERCK SHARP & DOHME CORP. 2004-04-15 US disclosed
WO-2002064559-A2 THROMBIN INHIBITORS MERCK & CO., INC. (US) 2002-08-22 WO disclosed
CN-1306523-A Substituted 6-aryl-3-thioxo-5-(thi) oxo-2,3,4,5-tetrahydro-1,2,4-triazines BASF AG (DE) 2001-08-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043000-A1 Immunosuppresive effects of pteridine derivatives TPMT, FKBP5, RRP15 MAPT 378/4885GAA 3004/4885ELANE 4800/4885
US-12624010-B2 Dihydrooxazole and thiourea derivatives modulating the NLRP3 inflammasome pathway NOD1, NLRP3, NLRP1 MAPT 690/4885GAA 4296/4885ELANE 2480/4885
US-11014963-B2 Trifluoromethylpropanamide derivatives as HTRA1 inhibitors HTRA1, HTR3E, HTR1F MAPT 3299/4885GAA 4005/4885ELANE 98/4885
US-20080045536-A1 FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS MAP3K3, MAP3K2, MAP4K3 MAPT 3886/4885GAA 4483/4885ELANE 4047/4885
US-20040073025-A1 Thrombin inhibitors F2, F11, F10 MAPT 4597/4885GAA 4576/4885ELANE 24/4885
US-20230250070-A1 DIHYDROOXAZOLE AND THIOUREA DERIVATIVES MODULATING THE NLRP3 INFLAMMASOME PATHWAY NLRP3, NOD1, NLRP1 MAPT 2088/4885GAA 3719/4885ELANE 2150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.